journal article·2026-04-26Open access

From Supplements to Therapeutics: Repurposing Antioxidant Compounds in the Management of NAFLD (Non-Alcoholic Fatty Liver Disease)

Rafailia-Eirini Theodorou, Nikiforos Vrettos, Panagiotis Theodosis-Nobelos

Applied Sciences· Volume 16· Issue 9

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide. Its main contributors are obesity, insulin resistance, diabetes and metabolic syndrome. Liver pathogenesis exacerbates when oxidative stress, inflammation, lipid accumulation, and attenuated autophagy signals coexist together with the main determinants of the liver disease. These findings may indicate that the suppression of the disease requires multi-targeting compounds to alleviate more than one factor, resulting in improved histopathological outcomes. This review studies natural compounds, given as supplements, with antioxidant and anti-inflammatory properties. The compounds included are vitamins, carotenoids, low-molecular-weight thiol-containing compounds, fatty acids and others that have been investigated for their pleiotropic activity alone or in combination. They act at different pathways and signals, and at gene expression control, modulating oxidative stress and inflammation, such as collagen, TNF-α, NF-κB, Nrf2 and PPARs genes. Their mechanism of action and characteristics may be encouraging treatment options as multi-targeting compounds for NAFLD and other diseases whose pathophysiology is closely related to metabolic syndrome. However, extensive study on their safety, toxicity, mechanisms of action and dosage regimen is needed before their final establishment as potential treatment options.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Liver Disease Diagnosis and Treatment · Drug-Induced Hepatotoxicity and Protection · Silymarin and Mushroom Poisoning

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmacy, School of Health Sciences, Frederick University, Nicosia 1036, Cyprus

References (100+)

Show source-provided references
1. Non-alcoholic fatty liver disease10.3109/10408363.2011.596521 ↗
2. Metabolism disrupting chemicals and metabolic disorders10.1016/j.reprotox.2016.10.001 ↗
3. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease10.1053/j.gastro.2019.11.312 ↗
4. Long-term follow-up of patients with NAFLD and elevated liver enzymes10.1002/hep.21327 ↗
5. Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis10.1016/j.metabol.2020.154203 ↗
6. Cirrhosis and mortality risks of biopsy-verified alcoholic pure steatosis and steatohepatitis: A nationwide registry-based study10.1111/j.1365-2036.2012.05091.x ↗
7. Relevance of autophagy to fatty liver diseases and potential therapeutic applications10.1007/s00726-017-2429-y ↗
8. Nutrient sensing nuclear receptors coordinate autophagy10.1038/nature13961 ↗
9. Functions of autophagy in hepatic and pancreatic physiology and disease10.1053/j.gastro.2011.04.038 ↗
10. Impaired autophagic flux is associated with increased endoplasmic reticulum stress during the development of NAFLD10.1038/cddis.2014.162 ↗
11. Endoplasmic reticulum stress involved in the course of lipogenesis in fatty acids-induced hepatic steatosis10.1111/j.1440-1746.2009.06086.x ↗
12. PYCR1 interference inhibits cell growth and survival via c-Jun N-terminal kinase/insulin receptor substrate 1 (JNK/IRS1) pathway in hepatocellular cancer10.1186/s12967-019-2091-0 ↗
13. Triggering and resolution of inflammation in NASH10.1038/s41575-018-0009-6 ↗
14. Lipid-Induced Endoplasmic Reticulum Stress Impairs Selective Autophagy at the Step of Autophagosome–Lysosome Fusion in Hepatocytes10.1016/j.ajpath.2016.03.003 ↗
15. Lipidomic biomarkers and mechanisms of lipotoxicity in non-alcoholic fatty liver disease10.1016/j.freeradbiomed.2019.05.029 ↗
16. Rinaldi, L., Pafundi, P.C., Galiero, R., Caturano, A., Morone, M.V., Silvestri, C., Giordano, M., Salvatore, T., and Sasso, F.C. (2021). Mechanisms of Nonalcoholic Fatty Liver Disease in the Metabolic Syndrome: A Narrative Review. Antioxidants, 10.10.3390/antiox10020270 ↗
17. Regulatory Effects and Molecular Mechanisms of Tea and Its Active Compounds on Nonalcoholic Fatty Liver Disease10.1021/acs.jafc.2c07702 ↗
18. Molecular Insights of Nonalcoholic Fatty Liver Disease Pathogenesis10.1089/jir.2023.0162 ↗
19. Nonalcoholic Fatty Liver Disease: Immunological Mechanisms and Current Treatments10.3748/wjg.v29.i32.4831 ↗
20. Mitochondrial Metabolic Dysfunction and Nonalcoholic Fatty Liver Disease: New Insights from Pathogenic Mechanisms to Clinically Targeted Therapy10.1186/s12967-023-04367-1 ↗
21. Insights into the Role and Interdependence of Oxidative Stress and Inflammation in Liver Diseases10.1155/2016/4234061 ↗
22. Mechanisms and Therapeutic Implications of Selective Autophagy in Nonalcoholic Fatty Liver Disease10.1016/j.jare.2024.01.027 ↗
23. Liu, Y., Zhang, M., and Wang, Y. (2025). Induction of Autophagy as a Therapeutic Breakthrough for NAFLD: Current Evidence and Perspectives. Biology, 14.10.3390/biology14080989 ↗
24. SIRT1: Harnessing Multiple Pathways to Hinder Nonalcoholic Fatty Liver Disease10.1016/j.phrs.2024.107155 ↗
25. Tauil, R.B., Golono, P.T., de Lima, E.P., de Alvares Goulart, R., Guiguer, E.L., Bechara, M.D., Nicolau, C.C.T., Yanaguizawa Junior, J.L., Fiorini, A.M.R., and Méndez-Sánchez, N. (2024). Metabolic-Associated Fatty Liver Disease: The Influence of Oxidative Stress, Inflammation, Mitochondrial Dysfunctions, and the Role of Polyphenols. Pharmaceuticals, 17.10.3390/ph17101354 ↗
26. The Bidirectional Immune Crosstalk in Metabolic Dysfunction-Associated Steatotic Liver Disease10.1016/j.cmet.2023.10.009 ↗
27. Vitamins C and E: Beneficial effects from a mechanistic perspective10.1016/j.freeradbiomed.2011.05.017 ↗
28. Vitamin E and nonalcoholic fatty liver disease
29. Role of vitamin E in nonalcoholic fatty liver disease10.1002/iub.1991 ↗
30. Effects of vitamin E treatment on peroxisome proliferator-activated receptor-alpha expression and insulin resistance in patients with nonalcoholic steatohepatitis: Results of a pilot study10.1111/j.1445-5994.2006.01295.x ↗
31. Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis10.1111/apt.12352 ↗
32. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis10.1056/NEJMoa0907929 ↗
33. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis10.1016/S1542-3565(04)00457-4 ↗
34. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis10.1111/j.1572-0241.2003.08699.x ↗
35. Plasma transforming growth factor-β1 level and efficacy of α-tocopherol in patients with non-alcoholic steatohepatitis: A pilot study10.1046/j.1365-2036.2001.01083.x ↗
36. Panera, N., Braghini, M.R., Crudele, A., Smeriglio, A., Bianchi, M., Condorelli, A.G., Nobili, R., Conti, L.A., De Stefanis, C., and Lioci, G. (2022). Combination treatment with hydroxytyrosol and vitamin E improves NAFLD-related fibrosis. Nutrients, 14.10.3390/nu14183791 ↗
37. Hydroxytyrosol: A natural compound with promising pharmacological activities10.1016/j.jbiotec.2019.12.016 ↗
38. Vitamin E and Nonalcoholic Fatty Liver Disease: Investigating the Evidence Through a Systematic Review
39. Vitamin E Treatment in NAFLD Patients Demonstrates That Oxidative Stress Drives Steatosis Through Upregulation of De Novo Lipogenesis10.1016/j.redox.2020.101710 ↗
40. Multifaceted role of tocotrienols in cardioprotection supports their structure–function relation10.1007/s12263-011-0227-9 ↗
41. A review on vitamin E natural analogues and on the design of synthetic vitamin E derivatives as cytoprotective agents10.2174/1389557520666200807132617 ↗
42. Effects of delta-tocotrienol supplementation on liver enzymes, inflammation, oxidative stress and hepatic steatosis in patients with nonalcoholic fatty liver disease10.5152/tjg.2018.17297 ↗
43. Yin, X., Chen, K., Cheng, H., Chen, X., Feng, S., Song, Y., and Liang, L. (2022). Chemical Stability of Ascorbic Acid Integrated into Commercial Products: A Review on Bioactivity and Delivery Technology. Antioxidants, 11.10.3390/antiox11010153 ↗
44. Van Gorkom, G.N.Y., Lookermans, E.L., Van Elssen, C.H.M.J., and Bos, G.M.J. (2019). The Effect of Vitamin C (Ascorbic Acid) in the Treatment of Patients with Cancer: A Systematic Review. Nutrients, 11.10.3390/nu11050977 ↗
45. Effect of Vitamin C Inhibiting Liver Fibrosis and Lipid Peroxidation in Biliary Obstruction of Wistar Rats10.18203/2349-2902.isj20203763 ↗
46. Wu, H., Guo, J.L., Yao, J.J., Yu, J.J., Xia, R.Y., Huang, W.Q., Tang, X., and He, G.M. (2023). Serum Vitamin C Levels and Risk of Non-Alcoholic Fatty Liver Disease: Results from a Cross-Sectional Study and Mendelian Randomization Analysis. Front. Nutr., 10.10.3389/fnut.2023.1162031 ↗
47. Vitamin C Deficiency Inhibits Nonalcoholic Fatty Liver Disease Progression through Impaired de Novo Lipogenesis10.1016/j.ajpath.2021.05.020 ↗
48. Evaluation of the Hepatoprotective Effect of L-Ascorbate 1-(2-Hydroxyethyl)-4,6-Dimethyl-1,2-Dihydropyrimidine-2-One Upon Exposure to Carbon Tetrachloride10.1007/s10517-017-3610-8 ↗
49. The Influence of the Xymedon Preparation (Hydroxyethyldimethyldihydropyrimidine) on the Rat Liver Recovery under Toxic Damage Induced by Carbon Tetrachloride10.1134/S1607672915030011 ↗
50. Study of Hepatoprotective Effects of Xymedon10.1007/s10517-013-2215-0 ↗
51. Vitamin D Inhibits Proliferation and Profibrotic Marker Expression in Hepatic Stellate Cells and Decreases Thioacetamide-Induced Liver Fibrosis in Rats10.1136/gut.2010.234666 ↗
52. Vitamin D3 (Cholecalciferol) Boosts Hydrogen Sulfide Tissue Concentrations in Heart and Other Mouse Organs10.3409/fb60_3-4.243-247 ↗
53. The Multifaceted Role of Ferroptosis in Liver Disease10.1038/s41418-022-00941-0 ↗
54. Vitamin D Supplementation Alleviates High Fat Diet-Induced Metabolic Associated Fatty Liver Disease by Inhibiting Ferroptosis Pathway10.1007/s00394-024-03554-0 ↗
55. Reda, D., Elshopakey, G.E., Albukhari, T.A., Almehmadi, S.J., Refaat, B., Risha, E.F., Mahgoub, H.A., El-Boshy, M.E., and Abdelhamid, F.M. (2023). Vitamin D3 Alleviates Nonalcoholic Fatty Liver Disease in Rats by Inhibiting Hepatic Oxidative Stress and Inflammation via the SREBP-1c/PPARα–NF-κB/IRS2 Signaling Pathway. Front. Pharmacol., 14.10.3389/fphar.2023.1164512 ↗
56. 1,25-Dihydroxycholecalciferol Down-Regulates 3-Mercaptopyruvate Sulfur Transferase and Caspase-3 in a Rat Model of Non-Alcoholic Fatty Liver Disease10.1007/s10735-023-10118-9 ↗
57. Federico, A., Dallio, M., Gravina, A.G., Diano, N., Errico, S., Masarone, M., Romeo, M., Tuccillo, C., Stiuso, P., and Morisco, F. (2020). The Bisphenol A-Induced Oxidative Stress in Non-Alcoholic Fatty Liver Disease Male Patients: A Clinical Strategy to Antagonize the Progression of the Disease. Int. J. Environ. Res. Public Health, 17.10.3390/ijerph17103369 ↗
58. Dallio, M., Diano, N., Masarone, M., Gravina, A.G., Patanè, V., Romeo, M., Di Sarno, R., Errico, S., Nicolucci, C., and Abenavoli, L. (2019). Chemical Effect of Bisphenol A on Non-Alcoholic Fatty Liver Disease. Int. J. Environ. Res. Public Health, 16.10.3390/ijerph16173134 ↗
59. González-Peña, M.A., Ortega-Regules, A.E., Anaya de Parrodi, C., and Lozada-Ramírez, J.D. (2023). Chemistry, Occurrence, Properties, Applications, and Encapsulation of Carotenoids—A Review. Plants, 12.10.3390/plants12020313 ↗
60. Hepatoprotective Potential of Carotenoid Meso-Zeaxanthin against Paracetamol, CCl4, and Ethanol-Induced Toxicity
61. Inhibitory Effects of Carotenoids on the Invasion of Rat Ascites Hepatoma Cells in Culture10.1016/S0304-3835(99)00418-8 ↗
62. Xiao, J., Wang, J., Xing, F., Han, T., Jiao, R., Liong, E.C., Fung, M.L., So, K.F., and Tipoe, G.L. (2014). Zeaxanthin Dipalmitate Therapeutically Improves Hepatic Functions in an Alcoholic Fatty Liver Disease Model through Modulating MAPK Pathway. PLoS ONE, 9.10.1371/journal.pone.0095214 ↗
63. Protective Effects of the Carotenoid Zeaxanthin in Experimental Nonalcoholic Steatohepatitis10.1007/s10620-009-0824-2 ↗
64. Anti-Inflammatory, Antioxidant, and Immunomodulatory Effects of Crocus sativus L. and Its Main Constituents10.1002/ptr.5622 ↗
65. Protective Effect of Crocin on Liver Toxicity Induced by Morphine
66. Crocetin Protects against Fulminant Hepatic Failure Induced by Lipopolysaccharide/D-Galactosamine by Decreasing Apoptosis, Inflammation, and Oxidative Stress in a Rat Model
67. Sreekanth, G.P., Chuncharunee, A., Yenchitsomanus, P.T., and Limjindaporn, T. (2020). Crocetin Improves Dengue Virus-Induced Liver Injury. Viruses, 12.10.3390/v12080825 ↗
68. Xu, Z., Lin, S., Gong, J., Feng, P., Cao, Y., Li, Q., Jiang, Y., You, Y., Tong, Y., and Wang, P. (2021). Exploring the Protective Effects and Mechanism of Crocetin from Saffron against NAFLD by Network Pharmacology and Experimental Validation. Front. Med., 8.10.3389/fmed.2021.681391 ↗
69. Kinetics, Pharmacokinetics, and Regulation of L-Carnitine and Acetyl-L-Carnitine Metabolism10.1196/annals.1320.003 ↗
70. Li, N., and Zhao, H. (2021). Role of Carnitine in Non-Alcoholic Fatty Liver Disease and Other Related Diseases: An Update. Front. Med., 8.10.3389/fmed.2021.689042 ↗
71. Peroxisome Proliferator-Activated Receptor Alpha Plays a Crucial Role in L-Carnitine Anti-Apoptosis Effect in Renal Tubular Cells10.1093/ndt/gfp258 ↗
72. Effects of L-Carnitine against Oxidative Stress in Human Hepatocytes: Involvement of Peroxisome Proliferator-Activated Receptor Alpha10.1186/1423-0127-19-32 ↗
73. L-Carnitine Prevents Hepatic Steatosis in Deep-Frying Oil-Treated Rat10.13005/bpj/2514 ↗
74. Glucosamine Regulation of Fibroblast Growth Factor 21 Expression in Liver and Adipose Tissues10.1016/j.bbrc.2020.06.070 ↗
75. Glucosamine Inhibits IL-1β Expression by Preserving Mitochondrial Integrity and Disrupting Assembly of the NLRP3 Inflammasome10.1038/s41598-019-42130-z ↗
76. Li, F., Zhang, Z., Bai, Y., Che, Q., Cao, H., Guo, J., and Su, Z. (2023). Glucosamine Improves Non-Alcoholic Fatty Liver Disease Induced by High-Fat and High-Sugar Diet through Regulating Intestinal Barrier Function, Liver Inflammation, and Lipid Metabolism. Molecules, 28.10.3390/molecules28196918 ↗
77. Zhao, G., He, F., Wu, C., Li, P., Li, N., Deng, J., Zhu, G., Ren, W., and Peng, Y. (2018). Betaine in Inflammation: Mechanistic Aspects and Applications. Front. Immunol., 9.10.3389/fimmu.2018.01070 ↗
78. Involvement of AMP-Activated Protein Kinase in Beneficial Effects of Betaine on High-Sucrose Diet-Induced Hepatic Steatosis10.1152/ajpgi.00133.2007 ↗
79. Dietary Betaine Promotes Generation of Hepatic S-Adenosylmethionine and Protects the Liver from Ethanol-Induced Fatty Infiltration10.1111/j.1530-0277.1993.tb00798.x ↗
80. Phosphatidylethanolamine N-Methyltransferase (PEMT) Knockout Mice Have Hepatic Steatosis and Abnormal Hepatic Choline Metabolite Concentrations Despite Ingesting a Recommended Dietary Intake of Choline10.1042/bj20021523 ↗
81. Betaine Attenuates Alcoholic Steatosis by Restoring Phosphatidylcholine Generation via the Phosphatidylethanolamine Methyltransferase Pathway10.1016/j.jhep.2006.08.024 ↗
82. Betaine Decreases Hyperhomocysteinemia, Endoplasmic Reticulum Stress, and Liver Injury in Alcohol-Fed Mice10.1016/S0016-5085(03)00276-2 ↗
83. Betaine, a Promising New Agent for Patients with Nonalcoholic Steatohepatitis: Results of a Pilot Study10.1111/j.1572-0241.2001.04129.x ↗
84. Betaine for Nonalcoholic Fatty Liver Disease: Results of a Randomized Placebo-Controlled Trial10.1002/hep.23239 ↗
85. Theodosis-Nobelos, P., and Rekka, E.A. (2022). The Multiple Sclerosis Modulatory Potential of Natural Multi-Targeting Antioxidants. Molecules, 27.10.3390/molecules27238402 ↗
86. Amides of Non-Steroidal Anti-Inflammatory Drugs with Thiomorpholine Can Yield Hypolipidemic Agents with Improved Anti-Inflammatory Activity10.1016/j.bmcl.2015.12.063 ↗
87. Lipoic Acid Prevents Liver Metabolic Changes Induced by Administration of a Fructose-Rich Diet10.1016/j.bbagen.2012.10.010 ↗
88. Sayaf, K., Battistella, S., and Russo, F.P. (2024). NLRP3 Inflammasome in Acute and Chronic Liver Diseases. Int. J. Mol. Sci., 25.10.3390/ijms25084537 ↗
89. Alpha-Lipoic Acid Alleviates NAFLD and Triglyceride Accumulation in Liver via Modulating Hepatic NLRP3 Inflammasome Activation Pathway in Type 2 Diabetic Rats10.1002/fsn3.2235 ↗
90. The Effects of α-Lipoic Acid on Liver Oxidative Stress and Free Fatty Acid Composition in Methionine-Choline Deficient Diet-Induced NAFLD10.1089/jmf.2013.0111 ↗
91. α-Lipoic Acid Prevents Non-Alcoholic Fatty Liver Disease in OLETF Rats10.1111/j.1478-3231.2012.02857.x ↗
92. Effect of Lipoic Acid on the Expression of Nonalcoholic Fatty Liver Disease-Associated Genes in the Liver of Rats Fed a Hypercaloric Choline-Deficient Diet10.5455/jabet.2024.d52 ↗
93. (+)-Lipoic Acid Reduces Mitochondrial Unfolded Protein Response and Attenuates Oxidative Stress and Aging in an in vitro Model of Non-Alcoholic Fatty Liver Disease10.1186/s12967-024-04880-x ↗
94. Oral α-Lipoic Acid Supplementation in Patients with Non-Alcoholic Fatty Liver Disease: Effects on Adipokines and Liver Histology Features10.1039/C9FO00449A ↗
95. Targeting Hepatic Sulfane Sulfur/Hydrogen Sulfide Signaling Pathway with α-Lipoic Acid to Prevent Diabetes-Induced Liver Injury via Upregulating Hepatic CSE/3-MST Expression10.1186/s13098-022-00921-x ↗
96. Zhu, X., Jiang, X., Li, A., Zhao, Z., and Li, S. (2017). S-Allylmercaptocysteine Attenuates Cisplatin-Induced Nephrotoxicity through Suppression of Apoptosis, Oxidative Stress, and Inflammation. Nutrients, 9.10.3390/nu9020166 ↗
97. Stępień, A.E., Trojniak, J., and Tabarkiewicz, J. (2024). Anti-Cancer and Anti-Inflammatory Properties of Black Garlic. Int. J. Mol. Sci., 25.10.3390/ijms25031801 ↗
98. S-Allylmercaptocysteine Reduces Carbon Tetrachloride-Induced Hepatic Oxidative Stress and Necroinflammation via Nuclear Factor Kappa B-Dependent Pathways in Mice10.1007/s00394-011-0217-0 ↗
99. Garlic-Derived S-Allylmercaptocysteine Is a Hepatoprotective Agent in Non-Alcoholic Fatty Liver Disease In Vivo Animal Model10.1007/s00394-012-0301-0 ↗
100. Garlic-Derived S-Allylmercaptocysteine Ameliorates Nonalcoholic Fatty Liver Disease in a Rat Model through Inhibition of Apoptosis and Enhancing Autophagy10.1155/2013/642920 ↗